IMC Chicago
TRVI icon

IMC Chicago’s Trevi Therapeutics TRVI Stock Holding History

IMC Chicago’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$315K Sell
26,400
-4,500
-15% -$50.4K ﹤0.01% 4540
2025
Q4 		$387K Sell
30,900
-2,500
-7% -$28.9K ﹤0.01% 3642
2025
Q3 		$306K Buy
+33,400
New +$250K ﹤0.01% 3406

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

IMC Chicago's TRVI Position: Q1 2026 in Review

IMC Chicago reduced its Trevi Therapeutics (TRVI) stake by 37% in Q1 2026, selling an estimated $162K and leaving 24,324 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #4626.

IMC Chicago first reported a position in TRVI in Q3 2025 and has held it in 3 quarters since. The position peaked at $486K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • IMC Chicago held 24,324 shares of Trevi Therapeutics worth $290K as of Q1 2026.
  • IMC Chicago sold 14,503 Trevi Therapeutics shares in Q1 2026, an estimated $162K.
  • Trevi Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #4626 holding.
  • IMC Chicago first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • IMC Chicago's Trevi Therapeutics position peaked at $486K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.